Tepezza

teprotumumab · Amgen Europe B.V.
AUTHORISED IN THE EU

What Tepezza is used for

Treatment of moderate to severe thyroid eye disease (TED).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Tepezza
Active substance
teprotumumab
Disease area
Graves Ophthalmopathy
Medicine group
Immunosuppressants;Monoclonal antibodies
ATC code
L04AG13
Marketing authorisation holder
Amgen Europe B.V.
Authorised in the EU since
2025

Official information

In the USA

Same active substance: Tepezza

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Tepezza used for?

Treatment of moderate to severe thyroid eye disease (TED).

What is the active substance in Tepezza?

Tepezza contains teprotumumab.

Who makes Tepezza?

The EU marketing authorisation holder is Amgen Europe B.V..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.